- Home
- GDYN vs EDIT Comparison
GDYN vs EDIT Comparison
Compare GDYN & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDYN | EDIT |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 509.3M | 432.8M |
| IPO Year | 2018 | 2016 |
Fundamental Metrics
Financial Performance| Metric | GDYN | EDIT |
|---|---|---|
| Price | $5.68 | $2.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $10.67 | $5.30 |
| AVG Volume (30 Days) | 1.9M | ★ 3.5M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | 37.50 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $111,283,000.00 | $31,937,000.00 |
| Revenue This Year | $10.16 | N/A |
| Revenue Next Year | $10.84 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $5.13 | $1.66 |
| 52 Week High | $12.86 | $4.54 |
Technical Indicators
Market Signals| Indicator | GDYN | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 35.66 | 48.33 |
| Support Level | $5.27 | $2.65 |
| Resistance Level | $6.11 | $2.73 |
| Average True Range (ATR) | 0.48 | 0.24 |
| MACD | -0.14 | -0.03 |
| Stochastic Oscillator | 2.47 | 29.31 |
Price Performance
Historical ComparisonAbout GDYN Grid Dynamics Holdings Inc.
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.